Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors (BZKF-Studie)

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (BZKF-Studie)

Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-Naive ROS1 positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)